Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review

Medicina

Jeffrey T. Gardner¹  Harry Dao¹  Leah Shin² 

[1] Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, CA 92708, USA;Loma Linda University School of Medicine, Loma Linda, CA 92708, USA;

关键词: linear IgA bullous dermatosis;    autoimmune diseases;    immunoglobulin A;    fluorescent antibody technique;    rituximab;    etanercept;   

DOI  :  10.3390/medicina57080818

来源: DOAJ

【 摘 要 】

Background and Objectives: Linear IgA disease (LAD) is a rare autoimmune blistering disease with linear IgA deposits along the basement membrane zone. Direct immunofluorescence remains the gold standard for diagnosis, but other diagnostic measures reported in recent literature have proven useful in the setting of inconclusive preliminary results. Dapsone is a commonly used treatment, but many therapeutic agents have emerged in recent years. The objective of this study is to provide a comprehensive overview of updates on the diagnosis and management of LAD. Materials and Methods: A literature search was conducted from May to June of 2021 for articles published in the last 5 years that were related to the diagnosis and management of LAD. Results: False-negative results in cases of drug-induced LAD and the presence of IgG and IgM antibodies on immunofluorescence studies were reported. Serration pattern analysis has been reported to be useful in distinguishing LAD from sublamina densa-type LAD. Rituximab, omalizumab, etanercept, IVIg, sulfonamides, topical corticosteroids, and others have been used successfully in adult and pediatric patients with varying disease severity. Topical corticosteroids were preferred for pediatric patients while rituximab and IVIg were used in adults with recalcitrant LAD. Sulfonamides were utilized in places without access to dapsone. Conclusion: In cases where preliminary biopsy results are negative and clinical suspicion is high, repeat biopsy and additional diagnostic studies should be used. Patient factors such as age, medical comorbidities, and disease severity play a role in therapeutic selection.

【 授权许可】

Unknown